Oncotelic evaluates IV everolimus candidate Sapu003 in Phase 1b trial for advanced solid tumors

ONCOTELIC THERAPEUTICS INC

ONCOTELIC THERAPEUTICS INC

OTLC

0.00
  • Oncotelic highlighted a peer-reviewed publication validating its Deciparticle nanoparticle platform for Sapu003, an investigational intravenous everolimus formulation.
  • Results were presented now via the journal article, covering manufacturing readiness, stability, preclinical activity, and broader applicability to poorly soluble drugs.
  • Sapu003 is being evaluated in an ongoing Phase 1b dose-escalation study in advanced mTOR-sensitive solid tumors.
  • The trial is assessing safety, pharmacokinetics, and early anti-tumor signals for weekly intravenous dosing in combination with exemestane.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncotelic Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290830PRIMZONEFULLFEED9753957) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.